Repligen Announces Analyst Day and Webcast
September 15 2017 - 7:30AM
Repligen Corporation (NASDAQ:RGEN) today announced that the Company
will host an institutional investor and analyst meeting on Friday,
September 29, 2017 in New York City from 7:30 a.m.-10:00 a.m. (ET).
The event theme, Bioprocessing Industry Trends and Growth Drivers,
will be discussed by Repligen management and outside expert Howard
Levine, Ph.D., founder and President of BioProcess Technology
Consultants.
A live webcast of the event will be accessible
through the Investor Relations section of Repligen’s website.
This webcast will be archived for a period of time following the
live event.
About Repligen CorporationRepligen
Corporation (NASDAQ:RGEN) is a global bioprocessing company that
develops and commercializes highly innovative products that deliver
cost and process efficiencies to biological drug manufacturers
worldwide. Our portfolio includes protein products (Protein A
affinity ligands, cell culture growth factors), chromatography
products (OPUS® pre-packed columns, chromatography resins, ELISA
kits) and filtration products (including XCell™ ATF systems,
TangenX™ Sius™ flat sheet TFF cassettes, and Spectrum KrosFlo™
hollow fiber TFF cartridges and systems). The Protein A ligands and
growth factor products that we produce are key components of
Protein A affinity resins and cell culture media, respectively.
Protein A affinity resins are the industry standard for downstream
separation and purification of monoclonal antibody-based
therapeutics. Growth factors are used in upstream processes to
accelerate cell growth and productivity. Our innovative line of
OPUS® chromatography columns, used in downstream processes for
bench-scale through clinical-scale purification needs, are
delivered pre-packed to our customers with their choice of resin
and to their bed height preferences. Our XCell™ ATF Systems,
available in stainless steel and single-use configurations,
continuously eliminate waste from a bioreactor to concentrate cells
and significantly increase productivity in upstream processes.
Single-use Sius™ TFF cassettes and hardware are used for biologic
drug concentration in downstream filtration processes. Spectrum
KrosFlo™ TFF cartridges and systems are used in both upstream and
downstream filtration processes. Repligen’s corporate headquarters
are in Waltham, MA (USA), with additional administrative and
manufacturing operations in Shrewsbury, MA, Rancho Dominguez, CA,
Lund, Sweden and Weingarten, Germany.
This press release may contain forward-looking
statements within the meaning of the federal securities laws.
Investors are cautioned that statements in this press release which
are not strictly historical statements including, without
limitation, statements identified by words like “believe,”
“expect,” “may,” “will,” “should,” “seek,” or “could” and similar
expressions, constitute forward-looking statements. Such
forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results to differ materially
from those anticipated, including risks discussed from time to time
in our filings with the Securities and Exchange Commission. We
expressly disclaim any responsibility to update any forward-looking
statements, except as required by law.
Source:Repligen CorporationSondra NewmanSenior Director Investor
Relations(781) 419-1881snewman@repligen.com
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024